The asthma and chronic obstructive pulmonary disease Dialogue

Introduction

Take This Event

This activity focuses on addressing real-world challenges in managing asthma and COPD, with a special emphasis on moderate-to-severe cases. It explores evidence-based strategies from SINA, GINA, and GOLD guidelines, highlights the role of single-inhaler triple therapy, and emphasizes optimizing patient outcomes through pharmacological and non-pharmacological approaches. Attendees will gain practical insights to bridge gaps in knowledge and enhance patient care.

Objectives

-Identify and address key barriers to effective asthma control, including environmental, behavioral, and healthcare-related challenges, to improve patient outcomes in diverse real-world settings.

- Implement personalized, evidence-based management strategies to optimize clinical outcomes and quality of life for moderate-to-severe asthma patients.

- Evaluate the efficacy and safety of single-inhaler triple therapy as a comprehensive approach to simplifying asthma management and reducing exacerbations.

- Apply guideline-directed pharmacological and non-pharmacological interventions to improve clinical outcomes and reduce exacerbations in Group E COPD patients.





For medical information, please contact GSK via [email protected]

To report Adverse Event/s associated with the use of GSK product/s, please contact us via [email protected].

To report Quality related product complaint/s associated with the use of GSK product/s, please contact us via [email protected].

CONNECT A Dialogue About Asthma And COPD is an STS and GSK Medical Collaborative Event

intended for healthcare professionals in Saudi Arabia.

© 2025 GSK group of companies or its Licensor.

About your privacy: GSK may monitor our technology tools and services (including email, phone, and other communications sent to and from GSK) in order to maintain the security of systems, and to protect our staff, customers and business partners from cyber threats and loss of information. Examples of these monitoring activities include checks for offensive materials, viruses and other malignant code, and unauthorized or unlawful activity. GSK monitoring is conducted with appropriate confidentiality controls and in accordance with local laws. You can learn about the information that we may process about you, and how we use your information, https://privacy.gsk.com/en-sa/privacy-notice/healthcare-professional/

You can also view GSK terms of use: https://terms.gsk.com/en-sa/pharmaceuticals/default/

Your name will be visible to others.

GSK: P.O Box 55850, Jeddah, 21544, Kingdom of Saudi Arabia

The event is recorded.

All event chairmen and speakers are not affiliated to GSK.

NX-SA-CAU-WCNT-250001 | Date of Preparation: Jan 2025

See Registration Policies, Cancellations & Refunds